Back to top
Viveve Medical (VIVE)
(Delayed Data from OTC)
$0.00 USD
0.00
49
0.00 (0.00%)
Updated Oct 30, 2024 02:49 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Balance Sheet
Fiscal Year End for Viveve Medical, Inc falls in the month of December.
All items in Millions except Per Share data.
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Equivalents | -99,999 | -99,999 | 19 | 7 | 13 |
| Receivables | NA | NA | 1 | 1 | 2 |
| Notes Receivable | NA | NA | 0 | 0 | 0 |
| Inventories | NA | NA | 1 | 3 | 5 |
| Other Current Assets | NA | NA | 1 | 2 | 2 |
| Total Current Assets | NA | NA | 22 | 13 | 22 |
| Net Property & Equipment | NA | NA | 2 | 3 | 3 |
| Investments & Advances | NA | NA | 1 | 1 | 1 |
| Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
| Deferred Charges | NA | NA | 0 | 0 | 0 |
| Intangibles | NA | NA | 0 | 0 | 0 |
| Deposits & Other Assets | NA | NA | 2 | 0 | 1 |
| Total Assets | NA | NA | 26 | 17 | 27 |
| Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
|---|---|---|---|---|---|
| Notes Payable | NA | NA | 0 | 0 | 0 |
| Accounts Payable | NA | NA | 1 | 1 | 2 |
| Current Portion Long-Term Debt | NA | NA | 0 | 1 | 0 |
| Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
| Accrued Expenses | NA | NA | 3 | 2 | 5 |
| Income Taxes Payable | NA | NA | 0 | 0 | 0 |
| Other Current Liabilities | NA | NA | 0 | 0 | 0 |
| Total Current Liabilities | NA | NA | 5 | 4 | 6 |
| Mortgages | NA | NA | 0 | 0 | 0 |
| Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
| Convertible Debt | NA | NA | 0 | 0 | 0 |
| Long-Term Debt | NA | NA | 5 | 5 | 4 |
| Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
| Other Non-Current Liabilities | NA | NA | 1 | 1 | 0 |
| Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
| Total Liabilities | NA | NA | 11 | 10 | 10 |
| Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
|---|---|---|---|---|---|
| Preferred Stock | NA | NA | 0 | 0 | 0 |
| Common Stock (Par) | NA | NA | 0 | 0 | 0 |
| Capital Surplus | NA | NA | 257 | 227 | 214 |
| Retained Earnings | NA | NA | -242 | -220 | -198 |
| Other Equity | NA | NA | 0 | 0 | 0 |
| Treasury Stock | NA | NA | 0 | 0 | 0 |
| Total Shareholder's Equity | NA | NA | 15 | 7 | 17 |
| Total Liabilities & Shareholder's Equity | NA | NA | 26 | 17 | 27 |
| Total Common Equity | 0 | 0 | 15 | 7 | 17 |
| Shares Outstanding | 10.70 | 10.70 | 10.50 | 2.10 | 0.70 |
| Book Value Per Share | 0.00 | 0.00 | 1.44 | 3.32 | 23.60 |
Fiscal Year End for Viveve Medical, Inc falls in the month of December.
All items in Millions except Per Share data.
| 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | -99,999 |
| Receivables | NA | NA | NA | NA | NA |
| Notes Receivable | NA | NA | NA | NA | NA |
| Inventories | NA | NA | NA | NA | NA |
| Other Current Assets | NA | NA | NA | NA | NA |
| Total Current Assets | NA | NA | NA | NA | NA |
| Net Property & Equipment | NA | NA | NA | NA | NA |
| Investments & Advances | NA | NA | NA | NA | NA |
| Other Non-Current Assets | NA | NA | NA | NA | NA |
| Deferred Charges | NA | NA | NA | NA | NA |
| Intangibles | NA | NA | NA | NA | NA |
| Deposits & Other Assets | NA | NA | NA | NA | NA |
| Total Assets | NA | NA | NA | NA | NA |
| Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
|---|---|---|---|---|---|
| Notes Payable | NA | NA | NA | NA | NA |
| Accounts Payable | NA | NA | NA | NA | NA |
| Current Portion Long-Term Debt | NA | NA | NA | NA | NA |
| Current Portion Capital Leases | NA | NA | NA | NA | NA |
| Accrued Expenses | NA | NA | NA | NA | NA |
| Income Taxes Payable | NA | NA | NA | NA | NA |
| Other Current Liabilities | NA | NA | NA | NA | NA |
| Total Current Liabilities | NA | NA | NA | NA | NA |
| Mortgages | NA | NA | NA | NA | NA |
| Deferred Taxes/Income | NA | NA | NA | NA | NA |
| Convertible Debt | NA | NA | NA | NA | NA |
| Long-Term Debt | NA | NA | NA | NA | NA |
| Non-Current Capital Leases | NA | NA | NA | NA | NA |
| Other Non-Current Liabilities | NA | NA | NA | NA | |
| Minority Interest (Liabilities) | NA | NA | NA | NA | NA |
| Total Liabilities | NA | NA | NA | NA | NA |
| Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
|---|---|---|---|---|---|
| Preferred Stock | NA | NA | NA | NA | NA |
| Common Stock (Par) | NA | NA | NA | NA | NA |
| Capital Surplus | NA | NA | NA | NA | NA |
| Retained Earnings | NA | NA | NA | NA | NA |
| Other Equity | NA | NA | NA | NA | NA |
| Treasury Stock | NA | NA | NA | NA | NA |
| Total Shareholder's Equity | NA | NA | NA | NA | NA |
| Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | NA |
| Total Common Equity | 0 | 0 | 0 | 0 | 0 |
| Shares Outstanding | 10.70 | 10.70 | 10.70 | 10.70 | 10.70 |
| Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |